{"id":11559,"date":"2025-10-21T14:45:34","date_gmt":"2025-10-21T14:45:34","guid":{"rendered":"https:\/\/polpharmabiologics.com\/?p=11559"},"modified":"2025-10-21T14:46:59","modified_gmt":"2025-10-21T14:46:59","slug":"presentation-of-a-ranibizumab-biosimilar","status":"publish","type":"post","link":"https:\/\/polpharmabiologics.com\/pl\/presentation-of-a-ranibizumab-biosimilar\/","title":{"rendered":"Polpharma Biologics announces commercial launch of Europe\u2019s first Pre-filled Syringe presentation of a ranibizumab biosimilar"},"content":{"rendered":"\n<p style=\"font-size:12px\"><em>Uprzejmie informujemy, \u017ce dokument jest dost\u0119pny wy\u0142\u0105cznie w wersji angloj\u0119zycznej.<\/em><\/p>\n\n\n\n<p><strong>Zurich, Switzerland<\/strong> \u2013 October 21, 2025 \u2013 Polpharma Biologics today announced Ranivisio\u00ae PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. <\/p>\n\n\n\n<p>Ranivisio\u00ae is the first Lucentis\u00ae biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics GroupBV and Formycon AG, is responsible for the development and licensing of Ranivisio\u00ae PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. <\/p>\n\n\n\n<p>The drug substance for Ranivisio\u00ae PFS is manufactured by Polpharma BiologicsS.A. &#8211; a contract development and manufacturing organization (CDMO) operatingunder the Rezon Bio brand, at its facilities in Poland. Rezon Bio is responsible for thecommercial supply of the drug substance, ensuring consistent quality and reliability. <\/p>\n\n\n\n<p>&#8222;The launch of Ranivisio\u00ae PFS in France is another important step in our mission to broaden access to biologic medicines. With the first Lucentis\u00ae biosimilar available ina pre-filled syringe in Europe, we are setting a new standard for ophthalmic treatment. We are proud to support our partners in bringing an innovative, high-quality therapy to patients and healthcare professionals,&#8221; said Anjan Selz, CEO of Polpharma Biologics.<\/p>\n\n\n\n<p><br><strong>About Polpharma Biologics<\/strong><\/p>\n\n\n\n<p>Polpharma Biologics is a biopharmaceutical company that develops, manufactures and commercializes biosimilars for global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch. Our international team of senior experts has proven experience in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Working with trusted CDMOs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners ensure access for patients to these medicines worldwide. Our mission is to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Uprzejmie informujemy, \u017ce dokument jest dost\u0119pny wy\u0142\u0105cznie w wersji angloj\u0119zycznej. Zurich, Switzerland \u2013 October 21, 2025 \u2013 Polpharma Biologics today announced Ranivisio\u00ae PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio\u00ae is the first Lucentis\u00ae biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":11570,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,1],"tags":[32],"class_list":["post-11559","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artykuly","category-bez-kategorii","tag-informacje-prasowe"],"_links":{"self":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/posts\/11559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/comments?post=11559"}],"version-history":[{"count":0,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/posts\/11559\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/media\/11570"}],"wp:attachment":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/media?parent=11559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/categories?post=11559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/tags?post=11559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}